Clasado Biosciences (‘Clasado’), a U.K headquartered international biotechnology company developing advanced prebiotics and gut health solutions for global food, dietary supplement and healthcare markets, has announced its Board Chairman, Moncef Slaoui, has been appointed Chief Advisor to the U.S Taskforce for COVID-19 vaccine development.
Leaving Glaxo SmithKline’s vaccine division in 2017, Slaoui became a biopharma venture capitalist joining lifesciences investment firm Medicxi, taking on numerous board positions including the Chairmanship of Clasado.
Operation Warp Speed first made headlines in late March detailing U.S efforts to deliver 100 million COVID-19 vaccine doses by the end of 2020, but this has subsequently been upgraded to 300 million. Slaoui’s primary mission as head of the task force will be to determine which vaccines are selected in the accelerated research and development programme that is seeking to manufacture more than one vaccine before trials are fully completed.
Per Rehné, CEO of Clasado, commented: “Obviously we’re delighted to see the excellent leadership Moncef provides being recognised in this way. It is a prestigious and highly challenging role. He has been fantastic to work with at Clasado providing tremendous insight and experience to our Board, as well as to me personally. We wish him every success and know that many millions of people are relying on the results of programmes like this to ensure the future of healthcare security.”
For more information on Clasado, please visit Clasado.com
